NCT00171145View on ClinicalTrials.gov

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

PHASE3CompletedINTERVENTIONAL
Enrollment

445

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

December 31, 2004

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

Darifenacin

Darifenacin 15 mg tablets once daily

DRUG

Placebo

Placebo tablets once daily

Trial Locations (1)

07936-108

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00171145 - A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. | Biotech Hunter | Biotech Hunter